Compass Pathways NASDAQ: CMPS has completed its application to the U.S. Food and Drug Administration for COMP360, its investigational synthetic psilocybin treatment for treatment-resistant depression, and expects to be ready to launch by the end of the year, subject to approval.
Speaking at a Jefferies event, CEO Kabir Nath said the company expects a launch in the first half of next year. He said two Phase 3 studies involving close to 900 patients produced statistically significant positive results, supported by an earlier Phase 2b study.
Compass has received a Commissioner’s National Priority Voucher, which Nath said could allow a rapid FDA review. The company also had an agreement for a rolling submission and review before receiving the voucher, he said.
FDA review and scheduling
Jefferies analyst Andrew Tsai cited Nov. 9 as the date the application was completed. Nath said the FDA had already been reviewing submitted modules and that Compass had no reason to believe the agency was abandoning its commitment to try to complete the review within one to two months of the completed submission.
Nath said Compass expects the application to be accepted with a prescription drug user fee, or PDUFA, date, but does not know when that will happen. He said the assigned date could reflect a standard six-month priority review, which the FDA might then complete earlier.
An FDA advisory committee meeting is unlikely, Nath said, though he emphasized that the decision belongs to the agency and that Compass would be prepared for one. He also said inspections of clinical sites and the contract research organization had been completed, while the manufacturing inspection process was underway.
Chief Commercial Officer Lori Englebert said a commercial launch would also depend on federal and state rescheduling. She said Compass anticipates a Schedule III designation, consistent with SPRAVATO, but has no insight into whether the Drug Enforcement Administration will act faster than its typical 90-day period after FDA approval.
Englebert said states representing about 93% of the population are positioned to reschedule within 30 days, while other states could also act quickly even if they are not legally bound to do so.
Launch plans and pricing
Compass plans to use treatment centers that already administer SPRAVATO, the approved treatment for treatment-resistant depression. Englebert said there are approximately 8,500 such sites, with about 500 being added per quarter, and the company expects 9,000 or more by its launch.
Englebert said COMP360 would require an estimated two to four doses annually, compared with 35 to 55 for SPRAVATO. She described the lower frequency as a potential reduction in the burden on patients and caregivers. CFO Teri Loxam said Compass expects to use the same rooms and personnel already used for SPRAVATO.
Englebert cautioned that COMP360’s risk evaluation and mitigation strategy, or REMS, has not been finalized. She said the FDA had directed Compass to use SPRAVATO’s REMS as a starting point, and the company does not expect existing sites to require different personnel or room configurations.
Compass plans to deploy about 100 sales representatives, as well as reimbursement and other field teams. Based on payer research, Englebert said the company is confident it can price COMP360 at a premium to SPRAVATO on an annual basis. She estimated SPRAVATO’s annualized price at $50,000 to $65,000.
Englebert said insurers will likely initially block coverage while they assess the new product, and Compass has prepared patient support and affordability programs. Loxam said providers should be able to use existing evaluation and management billing codes for monitoring while newer codes are evaluated, a process Englebert expects to take 12 to 18 months.
Competition and launch indicators
Englebert said Compass expects prescriptions to be trackable through major reporting outlets. Early indicators the company plans to watch include REMS certifications, new prescriptions, new prescribers and patient numbers. She said infrequent dosing would make total prescription counts harder to interpret in the early months.
Asked about a potential competing psilocybin product from Usona, Nath said Usona had not confirmed a filing, although one had been reported. He also said Compass believes Usona infringes its intellectual property and would take appropriate measures if the product were approved. Englebert noted that Usona’s program targets major depressive disorder, while Compass is pursuing treatment-resistant depression.
About Compass Pathways (NASDAQ:CMPS)
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.
While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.